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Abstract
Background: Synthetic peptides have played a useful role in studies of protein kinase substrates and
interaction domains. Synthetic peptide arrays and libraries, in particular, have accelerated the process.
Several factors have hindered or limited the applicability of various techniques, such as the need for
deconvolution of combinatorial libraries, the inability or impracticality of achieving full automation using
two-dimensional or pin solid phases, the lack of convenient interfacing with standard analytical platforms,
or the difficulty of compartmentalization of a planar surface when contact between assay components
needs to be avoided. This paper describes a process for synthesis of peptides and phosphopeptides on
microtiter plate wells that overcomes previous limitations and demonstrates utility in determination of the
epitope of an autophosphorylation site phospho-motif antibody and utility in substrate utilization assays of
the protein tyrosine kinase, p60c-src.
Results: The overall reproducibility of phospho-peptide synthesis and multiplexed EGF receptor (EGFR)
autophosphorylation site (pY1173) antibody ELISA (9H2) was within 5.5 to 8.0%. Mass spectrometric
analyses of the released (phospho)peptides showed homogeneous peaks of the expected molecular
weights. An overlapping peptide array of the complete EGFR cytoplasmic sequence revealed a high
redundancy of 9H2 reactive sites. The eight reactive phospopeptides were structurally related and
interestingly, the most conserved antibody reactive peptide motif coincided with a subset of other known
EGFR autophosphorylation and SH2 binding motifs and an EGFR optimal substrate motif. Finally, peptides
based on known substrate specificities of c-src and related enzymes were synthesized in microtiter plate
array format and were phosphorylated by c-Src with the predicted specificities. The level of
phosphorylation was proportional to c-Src concentration with sensitivities below 0.1 Units of enzyme.
Conclusions: The ability of this method to interface with various robotics and instrumentation is highly
flexible since the microtiter plate is an industry standard. It is highly scalable by increasing the surface area
within the well or the number of wells and does not require specialized robotics. The microtiter plate
array system is well suited to the study of protein kinase substrates, antigens, binding molecules, and
inhibitors since these all can be quantitatively studied at a single uniform, reproducible interface.
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Background
Phosphorylation and dephosphorylation of proteins are
major mechanisms mediating signal transduction
throughout the cell and are intimately involved in the reg-
ulation of cell growth, physiology, differentiation, and
death. Phosphorylation is accomplished by means of
kinases which when stimulated by an afferent signal trans-
mit the signal via phosphate transfer to the next site in a
pathway. In some cases phosphoprotein-protein interac-
tions take place that modulate signal transduction, e.g. by
revealing previously sequestered phosphoacceptor sites in
one or both of the interacting proteins, thus creating
branch points in pathways. Critical questions exist regard-
ing the identification of the true in vivo substrates of
kinases, identification of phosphotyrosine interaction
domains, and mapping the radiation of these protein
interactions throughout extremely complex networks.
Clearly new technologies capable of accelerating the proc-
esses for defining the interactions between kinases and
their substrates and modulators would be of great value.
Two highly productive approaches have been the determi-
nation of optimal substrate motifs favored by individual
kinases, by various combinatorial peptide library
approaches and, the use of antibodies to study phosphor-
ylated peptide motifs (reviewed in [1,2]). Synthetic pep-
tides have played a long and useful role in characterizing
kinase substrate sequences, particularly for the ser/thr
family, which is now seen to consist of a few distinct cate-
gory types, basophilic, acidophilic and proline directed.
Protein tyrosine kinases, on the other hand, are less well
defined by their natural substrates but make more use of
docking intermediaries to perform the task of substrate
recognition. Nevertheless, optimal substrates have been
found which can then aid in the search for the identity of
natural or in vivo targets and inhibitors of the kinase [3,4].
While capable of assessing mixtures of very large numbers
of random peptides, combinatorial methods require
deconvolution strategies, which can be time-consuming,
and technically demanding.
A second search strategy for functional peptides employs
arrays of spatially addressable peptides that can be tested
in situ, accelerating the deconvolution process when the
number of combinations is, or becomes more limited.
Peptide arrays capable of displaying diverse functions
including kinase substrate activity have been successfully
produced by two methods: in situ synthesis on planar
membranes or arrays of pins [5-10], or attachment of pre-
formed peptides as performed in a variety of microarray
printing procedures. While the existing synthetic methods
are capable of producing large numbers of peptides in
good purity, none are fully automatable. They require
manual intervention between each synthesis cycle and
thus are not totally automatable. Peptide synthesis in
microtiter plate wells would allow the use of fully auto-
mated robotic handlers. Further, arrays of peptides pro-
duced in a microtiter plate format, which is an industry
standard for numerous types of high throughput analyti-
cal procedures, could also be tested in automated multi-
plex fashion.
We present data here demonstrating the applicability of
an automated system for peptide design and synthesis in
microtiter plates to the production of peptides and phos-
phopeptides. We further demonstrate the capability of
these peptide arrays to be recognized correctly by specific
phospho-motif antisera and to serve as kinase substrates.
Results and discussion
(Phospho)peptide synthesis method
Previous work led to the development of a system for the
automated synthesis of peptide arrays on the inner sur-
faces microtiter plate wells [11-13], (Figure 1). However,
direct characterization of the synthesized peptides did not
become realizable until the recent availability of modern
high-sensitivity mass spectrometers. In this method
polymethylpentene (TPX) microtiter plates are activated
by oxidation with nitric acid, and made functional for
peptide synthesis by condensation with poly(D-lysine) (n
= 100), which serves as a free-floating support or poly-
meric handle containing an extended array of amino
groups. Each lysine side-chain then serves as an initiation
point for synthesis. The synthesized peptides are extended
from the well surface by their attachment through their
peptide carboxyl-termini, on a molecular tether of average
estimated length of 50 lysine subunits. This simply
assumes that each polylysine molecule is attached to the
surface through one bond at its midpoint. It is expected
that multiple attachment bonds between the surface and
a single polylysine chain can also form but would be min-
imized by the 2000-fold molar excess of polylysine over
attachment capacity used during the polylysine coating
step. Model experiments have shown that the polylysine
helical structure would be maintained in solution [14,15]
for most, if not all cases. If multiple attachment bonds
were formed then distal ends would prefer the helical
form while the sequences between attachment points
should also prefer the helical form up to the limits
imposed by torsional constraints, and depending on the
closeness of the attachment positions. Thus, the peptides
are well positioned spatially, to interact with a variety of
macromolecules such as antibodies and structures as large
as a cell surface. The lengths and sequences of the peptides
are programmable; the total elapsed cycle time to extend
each peptide by one residue for all 96 wells is 1 hour. The
process has been optimized with respect to activation con-
ditions, length and composition of the polymeric tether
and conditions for the handling and storage of the pre-
diluted amino acid derivatives and condensing agents.BMC Immunology 2005, 6:1 http://www.biomedcentral.com/1471-2172/6/1
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Stabilities exceeding two years have been achieved for all
reagents used. The capability of these peptides to be recog-
nized by antibodies, leading to the identification of
sequences and structures of the immunoreactive domains
of viral proteins and biological response modifiers has
been previously been demonstrated [11-13].
Reproducibility and quality of synthetic peptides
To evaluate the fidelity and reproducibility of peptide syn-
theses and ability of the synthetic peptide arrays to serve
as specific targets in sequence defined molecular affinity
interactions, a model system was chosen to provide
known test parameters. The EGF receptor system was
selected since it provided commercially available mono-
clonal antibodies with documented specificity for an acti-
vation state associated autophosphorylation site
(pY1173) and known sequence (NAEpYLRV). Testing was
begun with the monoclonal antibody 9H2 produced
against a peptide containing the NAEpYLRV sequence. An
array of alternating NAEYLRV and NAE(pY)LRV peptides
was prepared in a microtiter plate consisting of 12 8-well
strips. Monoclonal 9H2 antibody ELISA was performed
using three of the strips from the middle section of the
plate. It was found that the antibody reacted strongly with
the peptide wells containing phosphorylated tyrosine but
not with the non-phosphorylated peptide wells or control
Microtiter plate peptide array chemistry Figure 1
Microtiter plate peptide array chemistry Costar TPX microtiter plate strip well surfaces were oxidized with nitric acid, 
coated with polylysine and peptide synthesis is performed as described in Methods. Attachment of the polylysine chains to the 
wells and initiation of peptide synthesis takes place through the lysine ε-amino groups. The predicted polylysine helical segment 
shown is stabilized primarily through backbone H-bonding and synthesized peptides are depicted by red spheres.
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wells without peptide (Figure 2). For the three strips ELISA
means and (standard deviations) for the phosphotyrosine
peptides were 3.62(0.20), 3.64(0.25), 3.67(030) and for
the tyrosine peptides were 0.071(0.003), 0.068(0.007),
0.076(0.004). For wells containing no peptide, the values
for all three strips were 0.063(0.0006). The coefficients of
variation for all replicate sets ranged between 5% and 8%.
For evaluation of the fidelity and authenticity of phospho-
rylated and non-phosphorylated peptide products wells
containing NAEYLRV and NAEpYLRV were prepared as
before except that a cleavable linker was added to the
polylysine matrix before peptide synthesis. The synthe-
sized peptides were then cleaved from the surface with
TFA using conditions under which the protecting groups
were removed from the amino acid side-chains but not
from tyrosine phosphates. When the released peptide
products were concentrated and analyzed by MALDI-TOF-
TOF mass spectrometry it was found that both peptides
yielded essentially monodisperse m/z of the predicted
molecular weights, 1036.56 for NAEYLRV and 1170.62
for NAEpYLRV (Figure 3A and 3B, respectively;
[bis(dimethylamino)phosphono]-tyrosine species
shown). These data demonstrate high coupling efficiency
at each step of synthesis and stability of the activated
amino acids throughout the process.
Redundancy of an autophosphorylation site antibody 
epitope in the EGFR cytoplasmic domain
Since many of the twenty tyrosines found in the EGFR
cytoplasmic domain are known to serve as substrate or
SH2 binding site for other tyrosine kinases, it was decided
to test the specificity of the 9H2 antibody. To examine this
question, overlapping peptide arrays covering the trans-
membrane and cytoplasmic domains of the EGF receptor
were prepared. One array contained only
Reproducibility and specificity of multiplexed EGFR peptide synthesis and ELISA testing Figure 2
Reproducibility and specificity of multiplexed EGFR peptide synthesis and ELISA testing Peptides were synthe-
sized as microtiter plate array strips using either tyrosine or phosphotyrosine. Three replicate strips were used, each with no 
peptide in row A and alternating phosphotyrosine and tyrosine peptides in rows B to H. The strips were tested for reactivity 
with clone 9H2 antibody as described in Methods. ELISA results (x-axis) are plotted against tyrosine or phosphotyrosine repli-
cates for each strip (y-axis). Standard deviations varied between 5% and 10% of the means. Data are displayed without any 
correction.
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Mass spectrometric characterization of EGFR phosphopeptides produced in microtiter plate arrays Figure 3
Mass spectrometric characterization of EGFR phosphopeptides produced in microtiter plate arrays Panel A 
illustrates the mass spectrum of the NAEYLRV derivative ([M+H]1+ ion at m/z 1037.56) and panel B for the NAEpYLRV deriv-
ative ([M+H]1+ ion at m/z 1170.62). Peptides were released by incubation for 3 hours in TFA-H2O-triisopropylsilane, concen-
trated in vacuo and reconstituted for MALDI-TOF-TOF analysis. Under these conditions the bis(dimethylamino) phosphate 
protecting groups of phosphotyrosine were preserved and mass spectra were improved.
900 980 1060 1140 1220 1300
m/z
1037.56
966.52
982.51
R
e
l
a
t
i
v
e
 
I
n
t
e
n
s
i
t
y
 
(
%
)
0
20
40
60
80
100
A.
B.
900 980 1060 1140 1220 1300
m/z
0
20
40
60
80
100
R
e
l
a
t
i
v
e
 
I
n
t
e
n
s
i
t
y
 
(
%
)
1171.62
1117.53
1100.59
997.57BMC Immunology 2005, 6:1 http://www.biomedcentral.com/1471-2172/6/1
Page 6 of 15
(page number not for citation purposes)
phosphotyrosine and the other only tyrosine. The arrays
consisted of 92 peptides, each of which was 21 amino
acids in length and overlapped by 15 amino acids. In the
EGFR sequence arrayed, there are 20 unique occurrences
of tyrosine-containing peptide sequences. In the array,
each such sequence appears three to four times in progres-
sively overlapping fashion. Clone 9H2 antibody showed
high reactivity (from 9 to 57 times background) with eight
out of the twenty phosphotyrosine-containing sequences
(Figure 4, also [see Additional file 1]). In general, each
reactive peak was associated with three to four appear-
ances of the identifiable tyrosine as its position moved
progressively along the overlapping peptide sequences,
suggesting consistent reliable synthesis throughout the
synthetic process. None of the non-phosphorylated tyro-
sine-containing peptides showed any comparable reactiv-
ity with the monoclonal antibody 9H2 although a barely
detectable level of antibody reactivity with all peptides
containing tyrosine could be seen. There was no detecta-
ble reactivity against peptides not containing tyrosine [see
Additional file 1]. Steric hindrance by the attachment
matrix did not appear to be a significant problem in the
recognition of reactive peptide sequences separated by
just one, and two amino acids from the peptide carboxyl
terminus ([see Additional file 1], array positions 81, 91)
To assess the significance of these primary cross-reactivi-
ties a consensus table was constructed from 9H2 antibody
Distribution of 9H2 phosphotyrosine epitopes in EGFR Figure 4
Distribution of 9H2 phosphotyrosine epitopes in EGFR Overlapping peptide arrays were made and acetylated in micro-
titer plates using human EGF receptor residues 622–1186 (Swissprot database locus P0053 with leader sequence removed). 
Each array contained exclusively tyrosine or phosphotyrosine peptides and was composed of 92 peptides each of which was 21 
amino acids long and offset from its neighbor by 6 amino acids. Array peptide wells were reacted in multiplexed ELISA format 
with antibody 9H2 as described in Methods. Data are plotted without any corrections. Peptide sequences and raw data are 
listed [see Additional file 1].
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reactive and non-reactive sequences (Figure 5). A strong
preference for hydrophobic amino acids in the Y+1 posi-
tion is readily apparent with leucine the most preferred
appearing in 6 of 8 peptides, followed by isoleucine and
valine, both appearing once. At the Y-1 position glutamic
acid was the most preferred, appearing in 4 of 8 peptides,
followed by arginine, asparagine, aspartic acid, and
glutamine with one appearance each. Thus the preference
appears to be primarily for glutamic acid but other
hydrophilic amino acids were also accepted. There did not
Pattern of recognition of arrayed EGFR peptides by autophosphorylation site antibody (9H2) Figure 5
Pattern of recognition of arrayed EGFR peptides by autophosphorylation site antibody (9H2) Tyrosine sequence 
positions correspond to human EGF receptor residue positions (Swissprot P0053, leader sequence removed). Amino acids are 
color coded for acidic, basic, hydrophilic, and hydrophobic as red, blue, green and brown. *. For (phospho)peptide array com-
positions and quantitative results [see Additional file 1]. Footnotes: 1. autophosphorylation site [26-28], 2. PLC-gamma SH2 
domain binding[29], 3. GRB2/SH2 domain binding [30], 4. Shc, SHP1, PLC-gamma SH2 domain binding [31, 32], 5. Src phospho-
rylation site [33-35],6. AP2 [36, 37], 7. Cbl, SH2 domain binding [38-40], 8. Shc SH2 domain binding [31, 32, 41].
Tyrosine
Sequence
Position
Phosphotyrosine Sequence Derived from
Peptide Array
Position*
(active..fragment)
ELISA
Result*
Foot-
Notes
777 …GCLLD-pY-VREHK… 26, 27 +
789 …NIGSQ-pY-LLNWC… (27), 28, 29 +
803 …AKGMN-pY-LEDRR… (29), 30, 31 +
954 …RDPQR-pY-LVIQG… 55, 56, (57) +
992 …VDADE-pY-LIPQQ… (61), 62, (63) + 1, 2
1068 …LPVPE-pY-INQSV… 74, 75, (76) + 1, 2
1114 …VGNPE-pY-LNTVQ… (81), 82, 83, (84) +
1173 …AENAE-pY-LRVAP… (91), 92, 93 + 1, 4
703 …AFGTV-pY-KGLWI… 13, 14 -
730 …ILDEA-pY-VMASV… 20 -
845 …AEEKE-pY-HAEGG… 37, 38 - 5
867 …ILHRI-pY-THQSD… 41, 42 -
875 …SDVWS-pY-GVTVW… 42, 43 -
891 …FGSKP-pY-DGIPA… 45, 46 -
920 …CTIDV-pY-MIMVK… 50 -
974 …TDSNF-pY-RALMD… 59 - 1, 6
1045 …SFLQR-pY-SSDPT… 70, 71 - 1, 7
1086 …VQNPV-pY-HNQPL… 77, 78 - 1, 3
1101 …SRDPH-pY-QDPHS… 80, 81 - 5
1148 …LDNPD-pY-QQDFF… 88 - 1, 8
Amino acids are coded for acidic, basic, hydrophilic, and hydrophobic as red, blue, green and brown.BMC Immunology 2005, 6:1 http://www.biomedcentral.com/1471-2172/6/1
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appear to be any discernable pattern of preference at the
remaining peptide positions. The least common denomi-
nator among positive peptides therefore appears to be E/
(R, N, D, Q)-pY- L/(V, I), or E-pY-L in its predominant
form. Peptide sequence # 84 [see Additional file 1] which
lacked an acidic or hydrophilic amino acid at the pY-1
position was still strongly reactive demonstrating the
strong contribution of a hydrophobic amino acid in the
Y+1 position. However, since the peptide at position Y730
containing A(pY)V was not reactive ([see Additional file
1], Figure 5), 9H2 binding appears to involve more than
the pY-hydrophobic sequence alone.
Three of the 9H2 cross-reactive phosphotyrosines are clus-
tered within the C-terminal end of the receptor (992–
1173), are known autophosphorylation sites and are
known to be recognized by proteins containing Group III
SH2 binding domains [16] (e.g. p85, phospholipase Cγ1,
the tyrosine phosphatases, Figure 5), that similarly recog-
nize phosphotyrosines with hydrophobic amino acids at
the Y+1 position. Since some of the 9H2 cross-reactive
epitopes are not associated with phosphoacceptor activity
it suggests that the phosphoacceptor site specificities are
more stringently controlled than the 9H2 epitope or that
phosphoacceptor activity simply has not been demon-
strated yet. A similarity in the processes for recognition of
specificity determinants within the deduced epitope of the
9H2 autophosphorylation site antibody and optimal sub-
strate motif found for the EGF receptor [16-18], EEEEY-
FELV, may also exist.
Twelve of the twenty tyrosines present in the EGFR cyto-
plasmic domain were not reactive with 9H2. None of the
twelve conformed to the deduced 9H2-epitope motif,
although six out of 12 were involved with other aspects of
kinase signal transduction (Figure 5). As confirmation
that this was not a result of failure to incorporate phos-
photyrosine in the negative peptides a plate array contain-
ing all of the EGFR phosphotyrosine peptides was
constructed and tested against a group of commercial
phosphotyrosine antibodies prepared in various ways.
These results are shown in Figure 6. Antibodies 4G10,
AB8076, and PT101L were prepared using immunogens
which were chemically modified or haptenized and not
known to be sequence restricted and all reacted strongly
with all of the EGFR phosphopeptides. Antibody RDI-
egfract-1 was prepared against the activated EGF receptor
and known to be activation specific but not known to be
active against linear peptides. These results add support to
the specificity of the epitope deduced above and contrib-
ute additional useful information and reagents, namely
confirmation of the pan-specific nature of the phosphoty-
rosine antibodies as used in the microtiter plate peptide
array system
Tyrosine kinase activity on synthetic peptide substrates in 
microtiter plate arrays
To characterize the quantitative aspects of substrate phos-
phorylation by c-Src kinase, a panel of peptides based on
known substrate specificities of c-src and related enzymes
were synthesized in microtiter plate wells. Each peptide
extended from the polylysine backbone by an ε-amino
side-chain and by an additional C-terminal Cys unit.
Thus, all of the peptides were equally available to the
enzyme, with reduced steric hindrance and a uniform
presentation. Subsequently, 90 µL of reaction buffer con-
taining varying amounts of c-Src kinase were incubated
for 20 min at 30°, according to the manufacturer's
instructions. The wells were then washed with distilled
water and assayed for the presence of phosphotyrosine by
ELISA using a mixture of the broadly cross-reacting phos-
photyrosine antibodies previously described in Figure 6.
The peptide substrates EEIYGEFF [17] (Src,1) and
YIYGSFK [19] (Src,2) have been shown separately by
somewhat different combinatorial methods to have rela-
tively potent activity for protein tyrosine kinases and are
shown to be reactive here as well (Figure 7). (Src, 1) was
phosphorylated to a greater extent than (Src, 2) and
showed no decrease of reactivity even at 0.1 Unit of
enzyme, the lowest concentration used. The (Src, 1) vari-
ant peptides were chosen so that validation could be
made by direct comparison with the highly oriented pep-
tide chip system recently described [20]. The (Src, 1) vari-
ant peptide (-E) made by truncation of the N-terminus
still showed good reactivity, although much lower than
the longer (Src,1) peptide, and the (-Y) peptide in which
tyrosine was exchanged for phenylalanine showed no
reactivity as expected and required. The slight c-ABL tyro-
sine kinase substrate peptide IYAAPKKK [17] reactivity at
the highest c-Src input and negative protein kinase A sub-
strate peptide LRRASLGC [21,22] activity are consistent
with the level of cross-reactivities expected between famil-
ial and nonfamilial kinases. Three of the peptide sub-
strates showed dose-response characteristics conforming,
by nonlinear regression, to a one site binding model for (-
E), (Src, 2), and (ABL), with R2 equal to 0.98, 0.99, and
0.92. Activity of the most reactive peptide, (Src, 1) was
greater than expected based on quantity of enzyme used
in previously published work [23,24] and was at least 30
times more reactive than its truncated form (-E) [20]. By
extrapolation, c-Src activity would be detectable at con-
centrations as low as 0.01 Units of enzyme using the (Src,
1) substrate.
Conclusions
The method for production of synthetic peptide solid-
phase arrays in microtiter plates described here is capable
of making high quality peptides, as seen by mass spec-
trometry of the released unfractionated products. The pep-
tide synthesis method is completely automated and hasBMC Immunology 2005, 6:1 http://www.biomedcentral.com/1471-2172/6/1
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Reactivity of all EGFR phosphotyrosine peptides with a panel of pan-specific phosphotyrosine monoclonal antibodies Figure 6
Reactivity of all EGFR phosphotyrosine peptides with a panel of pan-specific phosphotyrosine monoclonal anti-
bodies Phosphotyrosine peptide sequences selected from the arrays used in Figure 4 [see Additional file 1] were synthesized 
in a new microtiter plate array and are identified on the y-axis. Each peptide and an empty control well were tested with each 
of the four antisera identified in the Figure legend, 4G10, ab8076, PT01L, and RDI-egfract-1 by standard ELISA as described in 
Methods. Data are plotted without any corrections
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Microtiter plate array peptides serve as substrates for p60c-src with specificity and concentration dependence Figure 7
Microtiter plate array peptides serve as substrates for p60c-src with specificity and concentration dependence 
Eight-well strips bearing six substrate peptide wells and two control wells were robotically synthesized ab initio, in microtiter 
plate format. All of the peptide substrates were initiated with Cys(Acm) to provide additional extension from the polylysine 
backbone and a common attachment site. The Cys-SH protecting group (Acm) remains in place and all peptides were 
acetylated at the amino terminus. Duplicate substrate strips were reacted with each 90-µL dilution of c-Src enzyme containing 
3, 1, 0.3, and 0.1 Units of enzyme. The wells were reacted for 20' at 30°, washed with distilled water and assayed by antibody 
ELISA for the presence of phosphotyrosine using a mixture of antibodies described in Figure 5. Nonlinear regression plots 
were computed in Prism and error bars represent the means ± 1 SD, which ranged between 3% and 7% of mean values. Itera-
tions for (ABL) did not converge. All data points were corrected by subtraction of values obtained from wells with no peptide.
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been greatly simplified by the use of standard automated
liquid handlers and the use of activated amino acid solu-
tions that may be prepared and stored in advance and
added just once at the beginning of the synthetic process.
In the present demonstration, 96 well microtiter plates
were used; but, 384, 1536, or containers of any well den-
sity compatible with the solvents and liquid handler may
be used. The solid phase peptide arrays produced on a
polylysine backbone were found to be of very high den-
sity, provide very low levels of nonspecific binding and
steric hindrance, and participate effectively in a variety of
biochemical reactions.
The strategy described here for the preparation of solid
phase synthetic peptide arrays in microtiter plate wells for
use in multiplexed assays offers many advantages in the
study of protein kinases, particularly in a research envi-
ronment. In a research environment combined cycles of
hypothesis generation and testing, with assay flexibility,
speed, quantitative accuracy and precision are of greater
concern than in large scale screening applications of large
numbers using limited, previously selected variables. The
industry standard microtiter plate format ensures compat-
ibility with a vast number of assay platforms and the poly-
lysine backbone with its extended three-dimensional
display provides a highly efficient, sterically unhindered,
and extremely low background display of the peptide
products.
Using 96-member peptide arrays of 21-mers created in
less than 24 hours, we have shown that the peptide array
synthesis provided a highly reproducible model for a tyro-
sine peptide, EGFR Y1173 and its phosphorylated coun-
terpart. Using a monoclonal antibody prepared against a
synthetic peptide representation of the Y1173 EGF recep-
tor autophosphorylation site, we have provided evidence
that, unexpectedly, the deduced epitope, E/HL-pY-L/HB
(where HL- is hydrophilic and HB is hydrophobic) is
highly redundant within the cytoplasmic domain. Three
of the eight antibody reactive sites have been previously
identified as autophosphorylation sites and are recog-
nized by Group III SH2 domain proteins (Figure 5) that
have similar specificity patterns. Furthermore, the EGFR
substrate sequence EEEEYFELV, derived by combinatorial
peptide optimization [17], resembles the E-Y-(hydropho-
bic) motif found in these studies. Thus there is a consist-
ent linkage between a subset of EGFR phosphotyrosine
sequences recognized by the 9H2 antibody, a subset of
sequences autophosphorylated by EGFR kinase, and
EGFR autophosphorylation sites recognized by the Group
III SH2 domain. There is a clear parallel between the 9H2
peptide epitope and the peptide substrate specificity of the
EGFR catalytic activity [16]. Songyang has further sug-
gested that the catalytic and SH2 domains of PTKs may
have converged to recognize similar sequences. So, ques-
tions regarding which site (or sites) the antibody actually
recognizes on stimulated EGF receptor molecules and
what other parallels might exist between 9H2 binding,
SH2 binding, and catalytic substrate selection become of
interest. At the cell protein level, 9H2 is specific by West-
ern blot for the stimulated EGF receptor. Furthermore,
there are preliminary data (Saxinger, unpublished)
suggesting that PDGF peptide sequences conforming to
the 9H2 binding sequence of (hydrophilic)-pY-(hydro-
phobic) deduced from EGFR phosphotyrosine peptides,
appear to be recognized differently by 9H2. While nine of
the twenty-seven PDGFR phosphotyrosine sequences sat-
isfied the (hydrophilic)-pY-(hydrophobic) sequence defi-
nition, and could be expected to be as reactive as those in
EGFR, only one showed comparable reactivity. Thus, the
binding determinants of 9H2 are more complex than the
simple epitope deduced from Figure 5. An intriguing pos-
sibility is that the 9H2 epitope may be a fairly simple one
but that its appearance, or access to it has been limited or
distorted in specific ways by spatially adjacent sequences
or structures that have evolved to create opportunities for
exploitation in biologically specific processes.
We have also successfully demonstrated the use of micro-
titer plate peptide arrays in faithfully reproducing the
known substrate phosphorylation specificities of c-Src
protein kinase. In these studies a broadly reactive phos-
photyrosine antibody ELISA detected phosphorylation.
Although a mixture of antibodies that were not known to
be sequence restricted was used, the possibility exists that
some tyrosine-containing peptides could become phos-
phorylated and be recognized less well than others. There-
fore in studies where the need for precise quantitation
outweighs the convenience and safety considerations of
ELISA, incorporation of radioisotopic phosphate would
provide an alternative. The microtiter plate format with
reactants bound to the well surface would provide a well-
contained and safe vehicle for washing and subsequent
measurement of radioactivity.
Thus, the microtiter plate array system is well suited to the
study of protein kinase substrates, antigens, related bind-
ing molecules, and inhibitors since these all can be quan-
titatively studied at a single uniform, reproducible
interface. For applications requiring larger numbers of
solid phase peptides, the synthetic process can easily be
transferred to more powerful workstations such as the
Biomek FX platform in which many plates with higher
well densities can be synthesized simultaneously and con-
ventional particle based substrates for peptide synthesis
can be manipulated using filter plates or magnetic devices
available for this system. Moreover, the current capacity of
approximately 150–380 pMoles/well can be considered
large enough for preparative or analytical applications
coupled with mass spectrometric analyses, such as affin-BMC Immunology 2005, 6:1 http://www.biomedcentral.com/1471-2172/6/1
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ity-based proteomic screening for ligand-protein interac-
tions. In this and other applications, such as assessment of
protease activity where strict isolation of adjacent compo-
nents is required, microtiter plate wells enjoy a significant
mechanical advantage over two-dimensional spotting or
other synthesis methods.
Methods
Materials
Solvents and reagents for peptide synthesis were obtained
as synthesizer grade from Applied Biosystems (Foster City,
CA). Specifically, these were N-methylpyrollidone
(NMP), 1 M N-Hydroxybenzotriazole (HOBT) in NMP, 1
M dicyclohexylcarbodiimide (DCC) in NMP, diisopropyl-
ethylamine (DIPEA), acetic anhydride, and trifluoroacetic
acid (TFA). NMP from this vendor was consistently free of
basic impurities and was stored over Molecular Sieve (4A)
after opening. NMP solutions were stored at -20C and
allowed to attain room temperature before opening.
FMOC-protected  α-amino acids were purchased from
Penninsula Laboratories (San Carlos, CA) and side-chain
substitutions were, Asn(Trt), Asp(OtBu), Cys(Acm) or
Cys(Trt), Gln(Trt), Glu(OtBu), His(Trt), Lys(Boc),
Ser(tBu), Thr(tBu) and Tyr(tBu). FMOC-Arg(Pbf), FMOC-
[bis(dimethylamino)phosphono))-tyrosine] [25], and
FMOC Rink amide (linker p- [(R,S)-a-[1-(9H-Fluoren-9-
yl)-methoxyformamido]-2,4-dimethoxybenzyl]-phe-
noxyacetic acid) were purchased from NovaBiochem.
Phenol, thioanisole, ethanedithiol (EDT), triisopropylsi-
lane (TIPS), and carbonyldiimidazole (CDI) were
obtained from Aldrich Chemical Co. (Milwaukee, WI).
Poly(D-Lys•HBr) (dp 100) and Poly(L-Lys•HBr) (dp 100)
were obtained from Sigma-Aldrich (St. Louis, MO). TPX
(polymethylpentene) 8-well strips, non-sterile, non-tissue
culture treated, were obtained from Costar on special
order (Cambridge, MA).
(Phospho)Peptide synthesis
Automated preparation of solid phase synthetic peptide
arrays in microtiter plates was performed as described pre-
viously [13] (Saxinger, US Patent 6031074, Feb. 29,
2000). Carboxyl functional groups are formed on the
hydrocarbon surface of Costar TPX microtiter plate strip
wells by oxidation with 70% nitric acid for two hours at
65°C or for two weeks at room temperature. Polylysine
chains are then attached to the surface by condensation
using 0.05 M carbonyldiimidazole in NMP for 30' at
20°C. Poly(L-Lys•Hbr) (PLL) or poly(D-Lys•Hbr) (PDL)
(1 mg/ml in 90% NMP-10% water) was neutralized with
DIPEA and reacted with the CDI-activated surface for 1
hour at 20°C and followed by 4°C overnight. Plates were
rinsed twice with water and twice with methanol, air-
dried, wrapped in plastic cling-wrap and stored at room
temperature. Peptide synthesis next takes place by the
sequential addition of Nα-FMOC amino acids activated
with DCC/HOBT as in conventional peptide synthesis
with the growing peptide chain covalently attached to the
polylysine chain through its carboxyl terminus. Stock
solutions of FMOC amino acids were prepared in advance
by dissolving 6 mmoles of each in 12 mL of NMP contain-
ing a 10% molar excess of HOBT, and stored at -20°C. The
solutions could then be used repetitively for at least three
months. Prior to peptide synthesis, the required amounts
of amino acid were diluted to 0.1 M in NMP, mixed with
an equimolar volume of 0.1 M DCC in NMP and allowed
to react for thirty min in 2 mL cryovials. The 20 mixtures
were then placed in a 24 tube rack on the Biomek 1000
workstation tablet for use during subsequent peptide syn-
thesis cycles. Synthesis automation is achieved through
software that receives input designating the peptide
desired in each of the 96 microtiter plate wells and creates
output files to indicate the quantity of reagents needed
and a set of Beckman Biomek 1000 arrays.bio files, each
member of the set directing the distribution of amino
acids in one of the sequential chain extension cycles. An
automated repetitive set of reagent transfers and washing
steps is then recycled using a new arrays.bio file for each
cyle until the peptide synthesis is complete. After synthe-
sis the peptides are usually capped by reaction with acetic
anhydride (1 mL in 10 mL of NMP containing 0.1 mL of
DIPEA per plate) before side-chain deprotection and test-
ing, in multiplex fashion, for reactivity. Side chain protect-
ing groups were generally removed with: 10 mL of TFA
+0.75 g of crystalline phenol + 0.5 mL of purified water +
0.5 mL of thioanisole +0.25 mL of ethanedithiol per plate,
incubated for three hours in a sealed container, washed
with ether, air-dried in a chemical fume hood, and stored
at -20°C in plastic wraps. For peptides not containing
Met, Trp, or Cys, TFA containing TIPS and H2O was used
(95%, 2.5%, and 2.5%, respectively).
Peptide synthesis capacity of microtiter plate wells
TPX microtiter plates were oxidized at either room tem-
perature or 60°C and reacted with polylysine. Peptide
quantities were estimated by two different methods. In
the first, the polylysine amino groups were modified with
the cleavable linker HMPB [4-(4-Hydroxymethyl-3-meth-
oxyphenoxy)-butyric acid] and FMOC-L-Cys(Acm) was
coupled to the HMPB-substituted support as described
above. Terminal amino groups were deprotected with
20% piperidine in NMP, washed with NMP and deriva-
tized with dabsyl chloride. The dabsyl-amino acid deriva-
tive was released with 95% TFA, harvested from multiple
wells by serial transfer, and measured by spectrophoto-
metric scanning in a Beckman DU65 using an extinction
coefficient of Dabsyl Chloride = 6.5 × 104 in TFA, λmax =
495). In the second method, FMOC-L-Ala was coupled
directly to the polylysine supports. The FMOC protecting
group was released in 20% piperidine, harvested from
multiple wells by serial transfer, and quantitated by fluor-BMC Immunology 2005, 6:1 http://www.biomedcentral.com/1471-2172/6/1
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imetric scanning in a Perkin Elmer LS50B using E(301) =
7800 (1 mM/ml). Values for spectral constants and coeffi-
cients were determined from standards dissolved in the
cleavage solvent. The solid phase capacity was 380
pMoles/well and the releasable capacity was 150 pMoles/
well.
Mass Spectrometry of synthetic array peptides
A polylysine coated TPX microtiter plate was modified by
preliminary reaction with FMOC-Rink Amide linker
(Novabiochem) to allow peptide cleavage after synthesis
using standard DCC/HOBT coupling conditions, as
described above. All peptides were initiated with C-termi-
nal Cys(Acm) to provide a constant initiation and cleav-
age environment. Peptides were released and deprotected
by incubation for 3 hours at room temperature in 100 µL
of TFA containing water, ethanedithiol and phenol, or
TFA containing water and triisopropylsilane. An addi-
tional 10 uL of water and 16 hours of incubation time are
required for deprotection of [bis(dimethyl-
amino)phosphono))-tyrosine] [25]. Solutions of released
peptides were concentrated by vacuum centrifugation and
0.25 µL of sample was co-crystallized with 0.25 µL of α-
cyano-4-hydroxycinnamic acid in 50% ACN, 1% trifluor-
oacetic acid and spotted directly on a stainless steel
matrix-assisted laser desorption ionization (MALDI)
plate. Mass spectra were acquired using an Applied Biosys-
tems 4700 MALDI-TOF/TOF mass spectrometer (Applied
Biosystems, Foster City, CA). MALDI mass spectra were
externally calibrated (<20 ppm) using a standard peptide
mixture.
Antibody recognition of microtiter plate arrayed peptides
Goat anti-mouse IgG (phosphatase conjugated) was pur-
chased from Kirkegaard & Perry (Gaithersburg, MD) and
Upstate Biotechnology (Lake Placid, NY). Murine
monoclonal antibody 9H2, purchased from Upstate Bio-
technology was prepared against a synthetic peptide con-
taining the EGFR autophosphorylation sequence at Y1173
and was certified by the manufacturer to be specific for
EGF-stimulated A431 cells by Western blot. Murine antis-
era prepared against phosphotyrosine were 4G10
(Upstate), ab8076 (Abcam, Ltd.), and PT01L (Oncogene
Research Products). Antiserum RDI-egfract-1 was pre-
pared against isolated tyrosine phosphorylated (acti-
vated) EGF receptor from EGF-challenged murine L-cells
(Research Diagnostics, Inc.). All sera were used according
to the manufacturer's recommendations and assayed by
indirect ELISA. The extent of reaction was determined
using a phosphatase assay kit from Kirkegaard & Perry.
Kinase assay
Peptide array substrate evaluations were performed using
p60c-src  protein-tyrosine kinase, Cat# PK03 (Oncogene
Research Products) according to the instructions in the
manufacturer's insert. In sequence, all wells received 30
µL of Kinase Assay Buffer (0.05 M HEPES, pH 7.5 + 0.1
mM EDTA + 0.015% BRIJ 35), 30 µL of appropriately
diluted p60c-src in Kinase Dilution Buffer (0.1 mg/mL BSA
+ 0.2% β-mercaptoethanol), 30 µL of ATP mix (0.03 M
MgCl2 +0.15 mM ATP) in Kinase Assay Buffer. Plates were
incubated at 30°C for 30 min, rinsed with distilled water
and assayed for the presence of phosphotyrosine as
described above. Each unit of p60c-src enzyme catalyzes the
incorporation of one pMole of phosphate into tyrosyl
residues.
List of abbreviations used
(9H2): antibody prepared against a synthetic peptide con-
taining the EGFR autophosphorylation site at Y1173
carbonyldiimidazole (CDI)
dicyclohexylcarbodiimide (DCC)
diisopropylethylamine (DIPEA)
EGF receptor (EGFR)
ethanedithiol (EDT),
N-Hydroxybenzotriazole (HOBT)
N-methylpyrollidone (NMP)
phosphotyrosine kinase (PTK)
Polymethylpentene (TPX)
trifluoroacetic acid (TFA)
triisopropylsilane (TIPS),
Amino acid and polypeptide abbreviations were in
accordance with IUPAC-IUB recommendations.
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